Please use this identifier to cite or link to this item:
|A cross-sectional study on medicinal products without commercial interest (MPWCI) in the Spanish market.
|Esteve Sala, Emili
Montes Barroso, Fátima
Bel Prieto, Elvira
Suñé i Negre, Josep M. (Josep Maria)
Anàlisi de medicaments
|BMJ Publishing Group
|Objective: To confirm that there is a defined group of products to be protected in the Spanish therapeutic arsenal known as 'medicinal products without commercial interest' (MPWCI) and propose the adoption of legal measures aimed at avoiding, or reducing, the lack of supply of said products. Design A cross-sectional study of proposed MPWCI based on a survey. The Spanish Agency of Medicines and Medical Devices (AEMPS) was asked for a list of presentations of medicines in order to identify those whose lack could have an impact on welfare. Setting: A search on the AEMPS website and a survey conducted among 44 companies belonging to Farmaindustria has allowed for the development of a proposal list of presentations that should continue to be marketed in Spain. Results: Products proposed as MPWCI are old (50% of them have an authorisation of more than 50 years) and are developed by active substances of chemical origin, parenterally administered much more frequently than the rest of the general market (44%vs6.6%, respectively). Unlike oral forms, injectable forms require adequate manufacturing facilities to guarantee the quality and sterility of the product, which naturally increases the cost of the product whose price is low or obsolete. The company experts have not valued the current price revisions as a sufficient enough mechanism to change the consideration of these medicines with respect to the interest on the part of some Marketing Authorisation Holders to maintain their commercialisation. Conclusions:As shown in the results, an upward revision of prices is necessary to contribute to the permanence of these presentations in the market, although some experts do not consider the current price revisions satisfactory enough to maintain these presentations in the market. Therefore, a specific regulation seems necessary to ensure the continuity on the market of these proposed products.
|Reproducció del document publicat a: https://doi.org/10.1136/bmjopen-2018-023054
|It is part of:
|BMJ Open, 2019, vol. 9, num. 1, p. 023054
|Appears in Collections:
|Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
This item is licensed under a Creative Commons License